Adis partnership with Amplion delivers biomarker data to AdisInsight users
The team behind AdisInsight have recently released a major enhancement, which sees drug and trial content in the platform enriched with curated biomarker data. The addition of this cutting-edge data is thanks to a strategic partnership between Adis and Amplion, the market-leaders in biomarker information.
Biomarkers play a vital role in drug development and now this invaluable information is fully integrated into the AdisInsight platform meaning that users can perform quick or advanced searches across the data, view it within drug and trial profiles, and include it within exports and alerts.
Greater efficiency in R&D programs
This exclusive combination of data sets supports greater efficiency in R&D programs as users are able to identify key biomarkers associated with a drug and understand how they were used in clinical trials to improve outcomes, increase likelihood of approval, and reduce timelines. The enriched data also provide greater insights into drug and disease landscapes, helping our customers to identify new opportunities.
Mirko Walter, Director of Product Management for Adis Business Intelligence states: “It is very important for us to work with a partner that shares our commitment to providing scientifically accurate content. The work that Amplion does in this space with BiomarkerBase is unparalleled and we are proud to be working with them to deliver an even more valuable service to our customers”.
Enabling more sophisticated analyses
Adis will also provide Amplion with granular drug information to enable more sophisticated analyses within BiomarkerBase. For example, users of BiomarkerBase will be able to organise their results by Drug Class, Mechanism of Action or Indication to assess how a biomarker fits within a therapy landscape. Users of AdisInsight are now able to follow links directly to BiomarkerBase from within drug or trial profiles to seek out further information.
The two teams will be working together over the coming months on a series of expert webinars that will help users to get the maximum value out of the data, and to gain a better understanding of the importance of biomarkers. To receive updates on the next session, or for a walkthrough of this content, please contact firstname.lastname@example.org.
By Gemma Ryder | Product Marketing Manager